pharmaspecialist
06 Jun 2018
Great news, but don't get carried away I think there must be near universal agreement that OXB did the right thing in monetising its technology for treating Parkinson's disease and the the net $25M payment sounds fair to me. However it's important to remember that its partner, Axovant/Roivant has no pedigree in developing drugs and lacks the expertise and clout of pharmaceutical companies. Roivant is run by an ex-hedge fund manager and as far as I am aware Axovant has not succeeded in developing any drugs so has no products on the market, although as it has only been going for about 4 years this is perhaps not surprising. The fact that Axovant IPO'd at $15 in 2015, almost doubled to $29 on the first day of trading, but is currently worth $1.75 per share is perhaps some indication of what the market thinks of the company. So a good deal for OXB but, in contrast to Novartis, I would suggest that Axovant is not the highest quality of partners.
d gaser
06 Jun 2018
Re: $843mLicensing agreement for pro savin Opps made a mistake again sorry about that. it should read I took my chances last week and I took some profit prior to the consolidation ,but this move has just paid me back due to the increase in my stock value. This is great news, and I'm very pleased to see this product, at long last has been given the chance to reach the market .which many sceptics said it wouldn't, so well done OXB. Its also possible OXB could now join the top 350 companies ,and if over the next few months we get further news, and we could enter the top 250 list, and all that could bring us.BE HAPPYDave ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- --=Oxford BioMedica inks up to $843m licensing agreement with Axovant SciencesStockMarketWire | Wed, 6th June 2018 - 08:10 Oxford BioMedica said it had entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialise a gene therapy developed by the company for Parkinson's disease.The agreement would see Axovant utilise Oxford BioMedica's LentiVector platform.Under the terms of the agreement, Oxford BioMedica would receive a $30m upfront payment (£22m) including $5m as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD.Oxford BioMedica was also eligible to receive $55m on achievement of development milestones and $757.5m on achievement of regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD..
d gaser
06 Jun 2018
$843mLicensing agreement for pro savin Well I took my chances last week and took some profit prior to the consolidation ,and this move has just paid me back in some of that profit in increased value. This is great news, and I'm very pleased to see this product at long last, will have the get the chance to reach the market .which many sceptics said it wouldn't, so well done OXB. OXB could now be into the top 350 companies ,and if over the next few months we get further news and the S/P continues to climb we could end up in the top 250 and all that means BE HAPPYDave ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- --=Oxford BioMedica inks up to $843m licensing agreement with Axovant SciencesStockMarketWire | Wed, 6th June 2018 - 08:10 Oxford BioMedica said it had entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialise a gene therapy developed by the company for Parkinson's disease.The agreement would see Axovant utilise Oxford BioMedica's LentiVector platform.Under the terms of the agreement, Oxford BioMedica would receive a $30m upfront payment (£22m) including $5m as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD.Oxford BioMedica was also eligible to receive $55m on achievement of development milestones and $757.5m on achievement of regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD..
techno foxx
06 Jun 2018
NASDAQ listing a NASDAQ listing might not be so far fetched after ?
green.as1953
06 Jun 2018
LTH I will continue to hold as in my humble opinion this is just the beginning.Good Luck to al LTH.
Roger Baron
06 Jun 2018
Re: Price Drop Good to see the moaning about volatility has stopped! Hope you all managed to top up on the dip.
warmfront
06 Jun 2018
New price target 10 pounds [link]
Chicken Lips
06 Jun 2018
Wow Over the years Ive lost, Ive lost more and thought that this could be something big. Then the doubts creep in but boy oh boy if only...this looks like the game changer.Now with a bigger small holding. My heart couldn't take the strain.Congrats to all who held put and kept the fait
riverside red
06 Jun 2018
Re: Billion dollar dealafter After what seems like a lifetime of being underwater I have finally gone blue.
warmfront
06 Jun 2018
Billion dollar deal This exceeds all my expectations. Wow. Just incredible.
warmfront
06 Jun 2018
Re: OXB RNS Wow again ! This is huge
loadsadough
06 Jun 2018
OXB RNS Well done Andy we have a good RNS today.OXB and Axovant Sciences Licence AgreementRNSRNS Number : 4166QOxford Biomedica PLC06 June 2018 Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson's DiseaseUnder the terms of the agreement, Oxford BioMedica will receive a $30 million upfront payment (approximately £22 million) including $5 million as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD. Oxford BioMedica is also eligible to receive $55 million upon the achievement of specified development milestones and $757.5 million upon the achievement of specified regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.Loadsadough
techno foxx
05 Jun 2018
Breast cancer immuneotherapy [link]
Andy Reilly
05 Jun 2018
Re: results from the JULIET clinical tri... Hi LoadsaD - well good on yer! I will probab;y double up on my modest holding of ITM (IF it drops a bit more!) but I feel my age at the mo, and feel a bit cautious - (Trump, Putin and Erdogwan, and a few other political leaders seem to have popped up to strut about.... and it makes me feel that there can only be more troule brewing!!! So I would want to wait for a big wobble (IF it came!) before adding anything.Lets hope OXB can do even better now it has consolidated - (personally it looks a good story to me, but it has become much more risky for the small time trader like me at £7+ - anyway I can only hope you have lots more success with OXB!) ATB
techno foxx
04 Jun 2018
just one c [link]
